Skip Navigation

European Heart Journal 2001 22(10):825-836; doi:10.1053/euhj.2001.2614
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braunwald, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The Denolin Lectures

Congestive heart failure: a half century perspective

E. Braunwaldf1

Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA

accepted January 17, 2001

f1 Correspondence: Eugene Braunwald, M.D., Brigham and Women's Hospital, 75 Francis Street, Boston MA 02115, U.S.A.

References

  1. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med. 1962;267:650–654
  2. Braunwald E, Chidsey CA. The adrenergic nervous system in the control of the normal and failing heart. Proc Roy Soc Med. 1965;58:1063–1066[ISI][Medline]
  3. Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med. 1965;39:442–451[CrossRef][ISI][Medline]
  4. Chidsey CA, Braunwald E, Morrow AG, Mason DT. Myocardial norepinephrine concentration in man. Effects of reserpine and of congestive heart failure. N Engl J Med. 1963;269:653–658[ISI][Medline]
  5. Chidsey CA, Sonnenblick EH, Morrow AG, Braunwald E. Norepinephrine stores and contractile force of papillary muscle from the failing human heart. Circulation. 1966;33:43–51[Abstract/Free Full Text]
  6. Chidsey CA, Kaiser GA, Sonnenblick EH, Spann JF, Braunwald E. Cardiac norepinephrine stores in experimental heart failure in the dog. J Clin Invest. 1964;43:2386–2393[ISI][Medline]
  7. Covell JW, Chidsey CA, Braunwald E. Reduction of the cardiac response to postganglionic sympathetic nerve stimulation in experimental heart failure. Circ Res. 1966;19:51–56[Abstract/Free Full Text]
  8. Epstein SE, Braunwald E. Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med. 1966;275:1106–1112[ISI][Medline]
  9. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913–919[Abstract/Free Full Text]
  10. Cohn JN, Olivari MT, Garberg V. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823[Abstract]
  11. Packer M, Bristow MR, Cohn JN. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  12. Lancet. 1999;353:9–13[CrossRef][ISI][Medline]
  13. Lancet. 1999;353:2001–2007[CrossRef][ISI][Medline]
  14. Pfeffer JM, Pfeffer MA, Mirsky E, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Nat Acad Sci. 1982;79:3310–3314[Abstract/Free Full Text]
  15. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 1985;57:84–95[Abstract/Free Full Text]
  16. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effects of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80–86[Abstract]
  17. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement (SAVE) Trial. N Engl J Med. 1992;327:669–677[Abstract]
  18. Circulation. 1998;97:2202–2212[Abstract/Free Full Text]
  19. Flather M, Yusuf S, Kober L. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581[CrossRef][ISI][Medline]
  20. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 991;69:475–482
  21. Rutherford JD, Pfeffer MA, Moye L. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. Circulation. 1994;90:1731–1738[Abstract/Free Full Text]
  22. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  23. Pfeffer MA, Domanski M, Rosenberg Y. Prevention of events with angiotensin converting enzyme inhibition: The PEACE Study design. Am J Cardiol. 1998;82:25H–30H[ISI][Medline]
  24. Grassi G, Cattaneo BM, Seravalle G. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation. 1997;96:1173–1179[Abstract/Free Full Text]
  25. Circulation. 2000;101:378–384[Medline]
  26. Francis GS, Cohn JN, Johnson G. Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT. Circulation. 1993;87:VI-40–VI-48
  27. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability, and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30–34[Abstract/Free Full Text]
  28. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717[Abstract/Free Full Text]
  29. Pacher R, Stanek B, Hulsmann M. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633–641[Abstract]
  30. Mulder P, Richard V, Derumeaux G. Role of endogenous endothelin in chronic heart failure: effect of longterm treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976–1982[Abstract/Free Full Text]
  31. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434–2440[Abstract/Free Full Text]
  32. Rouleau JL, Pfeffer MA, Steward DJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisnopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615–620[CrossRef][ISI][Medline]
  33. Dao, W, Krishnaswamy, P, Kazanegra, R, Utility of B-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting, J Am Coll Cardiol
  34. Colucci WS, Elkayam U, Horton DP. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–253[Abstract/Free Full Text]
  35. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;223:236–241
  36. Torre-Amione G, Kapadia S, Lee J. Tumor necrosis factor-{alpha} and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–711[Abstract/Free Full Text]
  37. Braunwald E, Bristow MR. Congestive Heart Failure: Fifty years of progress. Circulation. 2000;102:IV14–IV23
  38. Bryant D, Becker L, Richardson J. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-{alpha}. Circulation. 1998;97:1375–1381[Abstract/Free Full Text]
  39. Bozkurt B, Kribbs S, Clubb M Jr. Pathophysiologically relevant concentrations of tumor necrosis factor-{alpha} promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–1391[Abstract/Free Full Text]
  40. Deswal A, Bozkurt B, Seta Y. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, Entanercept) in patients with advanced heart failure. Circulation. 1999;99:3224–3226[Abstract/Free Full Text]
  41. Guillermo T-A, Stetson ST, Youker KA. Decreased expression of tumor necrosis factor-{alpha} in failing human myocardium after mechanical circulatory support. A potential mechanism for cardiac recovery. Circulation. 1999;100:1189–1193[Abstract/Free Full Text]
  42. Bristow MR, Ginsburg R, Minobe WA. Decreased catecholamine sensitivity and ß-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–211[Abstract]
  43. Waagstein F, Hjalmarson A, Varnauskas E. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;7:1022–1036
  44. Spann JF Jr, Buccino RA, Sonnenblick EH, Braunwald E. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res. 1967;21:341–354[Abstract/Free Full Text]
  45. Koide M, Nagatsu M, Zile MR. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. Circulation. 1997;95:1601–1610[Abstract/Free Full Text]
  46. Miyata S, Minobe WA, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and non-failing human heart. Circ Res. 2000;86:386–390[Abstract/Free Full Text]
  47. Heerdt PM, Holmes JW, Cai B. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation. 2000;:713–719
  48. Schwinger RHG, Munch G, Bolck B. Reduced Ca2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serine16 phospholamban phosphorylation. J Mol Cell Cardiol. 1999;31:479–491[CrossRef][ISI][Medline]
  49. Hasenfuss G, Schillinger W, Lehnart SE. Relationship between Na+-Ca2+exchanger protein levels and diastolic dysfunction of failing human myocardium. Circulation. 1999;99:641–648[Abstract/Free Full Text]
  50. Sabbah HN. Apoptotic cell death in heart failure. Cardiovasc Res. 2000;45:704–712[Free Full Text]
  51. Hein S, Kistin S, Heling A, Maeno Y, Schaper J. The role of the cytoskeleton in heart failure. Cardiovasc Res. 2000;45:272–278
  52. Weber KT. The heart's extracellular matrix. Cardiovasc Res. 2000;46:211–355[Free Full Text]
  53. Li YY, Feldman AM, Sun Y, McTiernan DF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998;98:1728–1734[Abstract/Free Full Text]
  54. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation. 2000;102:2700–2706[Abstract/Free Full Text]
  55. Pool PE, Spann JF Jr, Buccino RA, Sonnenblick EH, Braunwald E. Myocardial high energy phosphate stores in cardiac hypertrophy and heart failure. Circ Res. 1967;21:365–373[Abstract/Free Full Text]
  56. Coleman HN, Taylor RR, Pool PE. Congestive heart failure following chronic tachycardia. Am Heart J. 1971;81:790–798[CrossRef][ISI][Medline]
  57. Shen W, Asai K, Uechi M. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs. A compensatory role for the parallel loss of creatine. Circulation. 1999;100:2113–2118[Abstract/Free Full Text]
  58. Conway MA, Bottomley PA, Ouwerkerk R. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to low phosphocreatine/ATP ratios in humans. Circulation. 1998;97:1716–1723[Abstract/Free Full Text]
  59. Neubauer S, Horn M, Naumann A. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190–2196[Abstract/Free Full Text]
  60. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–1149[Abstract/Free Full Text]
  61. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1985;72:V-123–V-35
  62. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: Evidence for the "hibernating myocardium". J Am Coll Cardiol. 1986;8:1467–1470[ISI][Medline]
  63. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E. Medical and cellular implications of stunning, hibernation, and preconditioning: An NHLBI Workshop. Circulation. 1998;97:1848–1867[Free Full Text]
  64. Pagley PR, Beller GA, Watson DD. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy residual myocardial viability. Circulation. 1997;96:793–800[Abstract/Free Full Text]
  65. 2001 Heart and Stroke Statistical Update

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
R. R.J. van Kimmenade, J. L. Januzzi Jr, A. L. Baggish, J. G. Lainchbury, A. Bayes-Genis, A. M. Richards, and Y. M. Pinto
Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure: Redefining the Cardiorenal Interaction?
J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1621 - 1627.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. J. Akerman, M. Yaegashi, Z. Khiangte, A. T. Murugan, O. Abe, and J. D. Marmur
Bronchodilator effect of infused B-type natriuretic Peptide in asthma.
Chest, July 1, 2006; 130(1): 66 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. J. Murray, C. A. Lygate, M. A. Cole, C. A. Carr, G. K. Radda, S. Neubauer, and K. Clarke
Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart
Cardiovasc Res, July 1, 2006; 71(1): 149 - 157.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Wallis, C. A. Lygate, A. Fischer, M. ten Hove, J. E. Schneider, L. Sebag-Montefiore, D. Dawson, K. Hulbert, W. Zhang, M. H. Zhang, et al.
Supranormal Myocardial Creatine and Phosphocreatine Concentrations Lead to Cardiac Hypertrophy and Heart Failure: Insights From Creatine Transporter-Overexpressing Transgenic Mice
Circulation, November 15, 2005; 112(20): 3131 - 3139.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Andreas, H. Reiter, L. Luthje, A. Delekat, R. W. Grunewald, G. Hasenfuss, and V. K. Somers
Differential Effects of Theophylline on Sympathetic Excitation, Hemodynamics, and Breathing in Congestive Heart Failure
Circulation, October 12, 2004; 110(15): 2157 - 2162.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
C. Black
Heart failure: best practice and how to deliver it
Heart, October 1, 2002; 88(90002): ii1 - 1.
[Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braunwald, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?